Similar articles

• Benefit Design And Biosimilar Coverage In Medicare Part D: Evidence And Implications From Recent Reforms.

  Bertuzzi L, Maini L. Bertuzzi L, et al. Health Aff (Millwood). 2024 May;43(5):717-724. doi: 10.1377/hlthaff.2023.01297. Health Aff (Millwood). 2024. PMID: 38709961
• Generics and Biosimilars: Barriers and Opportunities.

  Scheckel CJ, Rajkumar SV. Scheckel CJ, et al. Mayo Clin Proc. 2021 Dec;96(12):2947-2957. doi: 10.1016/j.mayocp.2021.08.001. Epub 2021 Oct 30. Mayo Clin Proc. 2021. PMID: 34728057 No abstract available.
• Biosimilars for Management of Crohn Disease.

  Nielsen OH, Ainsworth MA. Nielsen OH, et al. Ann Intern Med. 2019 Jan 15;170(2):129-130. doi: 10.7326/M18-3060. Epub 2018 Dec 11. Ann Intern Med. 2019. PMID: 30535358 No abstract available.
• Biosimilars: how similar?

  Strand V, Cronstein B. Strand V, et al. Intern Med J. 2014 Mar;44(3):218-23. doi: 10.1111/imj.12292. Intern Med J. 2014. PMID: 24118772 Review.
• The rise of biosimilars: How they got here and where they are going.

  Patel D, Gillis C, Naggar J, Mistry A, Mantzoros CS. Patel D, et al. Metabolism. 2017 Oct;75:45-53. doi: 10.1016/j.metabol.2017.07.008. Epub 2017 Aug 7. Metabolism. 2017. PMID: 28939017 Review.